Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WNT974, LGX818, and Cetuximab in BRAF-mutant mCRC
NCT02278133Phase 2Completed
- Sponsor
- Array BioPharma
- Start
- Dec 2014
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of WNT974 in metastatic colorectal cancer (mCRC), sponsored by Array BioPharma. Started Dec 2014; status: completed.
02
Drugs
WNT974
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02278133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02278133.